Engflag

Buscopan Tablets

Quick links to important sections

Buscopan Tablets

Buscopan Tablets_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Buscopan Tablets

What is Buscopan Tablets?

Buscopan tablets contain the active substance hyoscine butylbromide, a compound derived from the belladonna alkaloid hyoscine. It belongs to a group of medicines known as antispasmodics, which are designed to alleviate involuntary muscle contractions within the digestive system.

Mechanism of Action

The medication works by relaxing the smooth muscles found in the walls of the stomach, intestines, and biliary tract. It achieves this by blocking the action of acetylcholine on muscarinic receptors located on these smooth muscle cells. Because it is a quaternary ammonium derivative, it does not easily cross the blood-brain barrier, which means its effects are primarily focused on the peripheral nervous system rather than the central nervous system.

Therapeutic Use

Buscopan tablets are used to provide relief from the symptoms of abdominal pain and discomfort associated with spasms of the gastrointestinal tract. This includes conditions such as:

  • Stomach and intestinal cramps: Reducing the intensity of muscle spasms that cause sharp or tugging pain.
  • Irritable Bowel Syndrome (IBS): Managing the periodic abdominal cramping and spasms often associated with this functional digestive disorder.
  • Biliary colic: Relieving spasms in the bile ducts.

By targeting the underlying muscle tension, the medication helps to ease the cramping sensation and associated discomfort, facilitating a more relaxed state of the digestive tract.

What side effects are possible with Buscopan Tablets?

Possible Side Effects and Safety Information

Adverse reactions to hyoscine butylbromide are primarily linked to its anticholinergic properties and are classified by frequency using standard regulatory conventions (e.g., Common, Uncommon, Rare, Not Known).

Official Adverse Reactions and Frequencies

Classification System-Organ Class Documented Adverse Reaction
Common Cardiac Disorders Tachycardia (increased heart rate)
Common Gastrointestinal Disorders Dry mouth, Constipation
Uncommon Skin and Immune Hypersensitivity, Urticaria (hives), Skin rash, Abnormal sweating
Rare Renal and Urinary Disorders Urinary retention (inability to pass urine)

Serious Adverse Reactions

The most clinically significant reactions documented, predominantly from post-marketing reports (and classified as Not Known frequency), are severe anaphylactic reactions and anaphylactic shock, which may include difficulty breathing (dyspnea) and sometimes result in a fatal outcome. The label also lists angioedema as a serious hypersensitivity reaction.

Regulatory Restrictions

Official regulatory documents list several conditions where Buscopan Tablets must not be used. These absolute contraindications include narrow-angle glaucoma, megacolon, myasthenia gravis, and certain obstructive conditions of the gastrointestinal tract (e.g., mechanical stenosis, paralytic ileus). The medicine is also restricted in patients with prostatic hypertrophy with urinary retention or other obstructive uropathy.

Furthermore, the label states that this medicine should not be taken on a continuous daily basis or for extended periods without investigating the underlying cause of the abdominal pain.

This framework of officially documented side effects, categorized by frequency and restricted by absolute contraindications, defines the official safety profile of the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdosage with hyoscine butylbromide primarily through its documented anticholinergic effects. Serious signs of poisoning have generally not been observed following acute oral overdosage in humans, according to prescribing information. Nonetheless, immediate medical attention is required if an overdose is suspected or if more tablets than recommended are taken.

Documented Overdose Manifestations

Overdosage may present with specific signs reflecting excessive anticholinergic action. These manifestations include:

  • Urinary retention
  • Dry mouth
  • Tachycardia (fast heart rate)
  • Transient visual disturbances (accommodation disorders)
  • Reddening of the skin

Required Emergency Actions and Management

If signs of overdosage occur, patients must seek medical advice immediately. Regulatory documents outline specific supportive and symptomatic measures for management:

  • Supportive Treatment: General symptomatic and supportive treatment is indicated.
  • Procedural Steps: For oral poisoning, gastric lavage followed by medicinal charcoal and magnesium sulfate is described. Procedures like catheterisation may be necessary for urinary retention.
  • Severe Complications: Treatment sections mention managing cardiovascular complications and addressing potential respiratory paralysis (which may require intubation and artificial respiration). The symptoms of overdosage respond to parasympathomimetics.

Therapeutic Uses of Buscopan Tablets

Quick Facts

  • Relieves discomfort associated with muscle spasms.
  • Manages symptoms of cramping in the gastrointestinal and genitourinary tracts.
  • Used for pain management linked to conditions like Irritable Bowel Syndrome (IBS).

Buscopan Tablets are a treatment option used for the symptomatic management of pain and discomfort that is associated with smooth muscle spasms. This medicine helps address the functional symptoms of cramping in the gastrointestinal (GI) and genitourinary tracts.

The therapeutic application of the tablets focuses on managing specific episodes of abdominal pain. It is indicated for the relief of smooth muscle spasm, or cramping, which can occur in the stomach and intestines. Furthermore, it is clinically used to help manage the symptoms of Irritable Bowel Syndrome (IBS), including associated abdominal discomfort.

Hyoscine butylbromide, the active substance, is used for these specified therapeutic indications.

Regulatory References

  1. Health Canada therapeutic overview

Eligibility and Restrictions for Use

Buscopan tablets, which contain the active ingredient hyoscine butylbromide, are typically used by most adults and children aged 6 years and over to relieve stomach and bowel cramps. Some brands intended for Irritable Bowel Syndrome (IBS) relief are specifically for adults and children aged 12 years and over and should only be used if a diagnosis of IBS has been confirmed by a doctor.

Contraindications and Cautions

This medication is not suitable for everyone. Do not take Buscopan tablets if you have:

  • An allergy to hyoscine butylbromide or any other ingredients.
  • Glaucoma (an eye condition with high pressure).
  • Myasthenia gravis (a condition causing severe muscle weakness).
  • A blockage in the bowel or stomach, such as paralytic or obstructive ileus, or a very enlarged bowel (megacolon).

Additionally, caution is required and medical advice should be sought if you have conditions such as a very fast heart rate (tachyarrhythmia), an enlarged prostate leading to difficulty or pain when passing urine, or a fever. Use during pregnancy and breastfeeding is generally advised against due to limited safety data. The tablets also contain sucrose and are contraindicated in patients with rare hereditary fructose intolerance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information documents interactions between hyoscine butylbromide and specific classes of medicines, primarily based on pharmacodynamic and gastrointestinal effects.

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions: Anticholinergic Agents, Dopamine Antagonists, Beta-adrenergic Agents, and other Oral Medications.
Specific interacting medicines (if explicitly listed): Tricyclic and tetracyclic antidepressants, antihistamines, antipsychotics, quinidine, amantadine, disopyramide, ipratropium, tiotropium, metoclopramide, domperidone, and alcohol.
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic: Additive or antagonistic effects on cholinergic pathways. Pharmacokinetic: Alteration of systemic absorption due to reduced gastrointestinal motility.
Timing-based interaction rules (if applicable): None stated as mandatory for the tablet formulation.
Interaction-related restrictions: Co-administration with alcohol may increase the chance of side effects, such as drowsiness.

Resulting Interaction Structure

Official regulatory documents state that medicines with anticholinergic properties may intensify the anticholinergic effect of hyoscine butylbromide. Conversely, co-administration with dopamine antagonists (e.g., metoclopramide) may diminish the effects of both medicines on the gastrointestinal tract. The tachycardic effects of beta-adrenergic agents may be enhanced. Furthermore, due to reduced gastrointestinal motility, this medicine may cause the delayed systemic absorption of other concurrently administered oral medicines.

Mechanism of Action

How Buscopan Tablets Works: Pharmacodynamic Mechanism

Buscopan tablets (hyoscine butylbromide) exert their action through the modulation of peripheral cholinergic signaling in the smooth muscle of the gastrointestinal and genitourinary tracts. The molecule functions as an antagonist at post-ganglionic muscarinic receptors (M1-M3).

This specific receptor interaction competitively blocks the binding of the neurotransmitter acetylcholine. Acetylcholine binding normally promotes Gq-protein signaling that triggers an increase in intracellular calcium, leading to muscle contraction. By interrupting this pathway, hyoscine butylbromide suppresses the signaling sequence necessary for contraction.

This mechanistic cascade alters the amplitude of smooth muscle contraction by directly reducing both tonic and propulsive contractile activity in the viscera. The resulting decrease in smooth muscle tone is a predictable physiological consequence at the site of action. Due to its quaternary ammonium structure, the compound exhibits limited systemic absorption and does not readily cross the blood-brain barrier.

Dosage and Administration Information

How to Use Buscopan Tablets

Buscopan tablets, containing hyoscine butylbromide, are administered exclusively via the oral route for symptomatic management of smooth muscle spasms. This medicine is intended strictly for short-term, symptomatic use and is not suitable for continuous daily consumption without medical review.

Administration Method and Dosage

To ensure proper administration, the tablet must be swallowed whole with water and should not be broken, crushed, or chewed. The medicine can be taken with or without food.

Population Typical Dose (per dose) Maximum Frequency Maximum Daily Dose
Adults (ge 12 years) 10 mg to 20 mg (1 to 2 tablets) Up to 4 times daily 80 mg (8 tablets)
Children (6 to 11 years) 10 mg (1 tablet) Up to 3 times daily Not to exceed 30 mg

Duration and Procedural Rules

Dosage is taken as needed for acute episodes, typically maintaining an interval of 4 to 6 hours between doses. If the condition is not relieved, or if symptoms worsen after a period of two weeks of treatment, the medicine should be discontinued and further medical advice sought.

If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose; in this instance, the missed dose must be skipped. A double dose must never be taken to compensate for a forgotten dose.

Recent Clinical Evidence

Evidence for use in Irritable Bowel Syndrome (IBS)

Research has examined Buscopan Tablets in individuals diagnosed with Irritable Bowel Syndrome (IBS), focusing on patient-reported outcomes for abdominal cramping and physical discomfort. Studies were evaluated in controlled trials, comparing data related to the study drug to placebo. Findings describe patterns where these data varied from placebo regarding outcomes related to physical discomfort. Evidence quality varies, and research does not determine whether an individual will respond similarly.

Evidence for use in General Stomach and Abdominal Cramping

Studies have explored the role of Buscopan Tablets in relation to general abdominal discomfort and spasm, often in individuals experiencing acute, non-specific episodes. Findings indicate that the use of Buscopan Tablets was observed during changes in outcomes related to physical discomfort. However, the causes of cramping vary widely, meaning results apply only to the populations studied, and certainty remains low regarding universal applicability.

Long-term studies and follow-up

Research has primarily focused on short treatment courses, meaning follow-up durations were limited, and long-term effects are not fully established. Data are still emerging regarding the consistency of any observed changes in outcomes related to physical discomfort over time. The picture of prolonged management for conditions characterized by fluctuating manifestations remains incomplete.

Evidence in special populations

Research has studied the use of Buscopan Tablets in various age groups, including older adults and children. The data for certain groups remain insufficient; for instance, evidence is limited for specific comorbid conditions or individuals who are pregnant. Subgroup findings are often uncertain due to the relatively modest sample sizes found in these specific population studies.

What is still uncertain about Buscopan Tablets

Several areas remain uncertain. Long-term effects are not fully established, and comparative evidence is lacking against many other potential treatments. The findings were mixed concerning data patterns related to outcomes reflecting daily functioning or activity level. More research is needed to address these limitations and improve the understanding of the evidence landscape.

Key Studies & References

  1. Irritable bowel syndrome in adults: diagnosis and management (NICE Guideline NG129)

How should Buscopan Tablets be stored and disposed of?

How to Store and Dispose of Buscopan Tablets

Official regulatory guidelines define specific conditions for storing and disposing of Buscopan (hyoscine butylbromide) tablets to ensure product stability.

Storage Requirements

Buscopan tablets must be stored at or below 25 C or 30 C, depending on regional labeling. The product requires protection from light and moisture and must be stored in the original package.

Condition Regulatory Requirement
Temperature Store below 25 C or 30 C
Protection Protect from light; keep dry
Safety Keep out of the sight and reach of children
Stability Do not use after the labeled expiry date

Disposal Instructions

Expired or unused Buscopan tablets must not be disposed of via wastewater or household waste. Regulatory procedures require that the medicine be returned to a pharmacist for safe and appropriate disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Buscopan Tablets found in:

A-Z Index: